50593-30-1

Basic information

• Product Name: 6-AMINO-2-METHYL-2H-INDAZOLE
• Synonyms: 6-AMINO-2-METHYL-2H-INDAZOLE;6-AMINO-2-METHYLBENZO[C]PYRAZOLE;2-Methyl-2H-indazol-6-amine;2-Methyl-2H-indazole-6-amine;6-Amino-2-methyl-2H-indaz...;6-aMine-2-Methyl-2H-indazole
• CAS NO: 50593-30-1
• Molecular Formula: C₈H₉N₃
• Molecular Weight: 147.18
• Product Categories: Building Blocks;Indazole
• Mol File: 50593-30-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 148-150
• Boiling Point: 354.8°C at 760 mmHg
• Flash Point: 168.4°C
• Appearance: Yellow to green/Crystalline Powder
• Density: 1.27g/cm³
• Vapor Pressure: 3.26E-05mmHg at 25°C
• Refractive Index: 1.667
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.31±0.10(Predicted)
• CAS DataBase Reference: 6-AMINO-2-METHYL-2H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMINO-2-METHYL-2H-INDAZOLE(50593-30-1)
• EPA Substance Registry System: 6-AMINO-2-METHYL-2H-INDAZOLE(50593-30-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 50593-30-1(Hazardous Substances Data)

Usage

General Description

6-Amino-2-methyl-2H-indazole is a chemical compound with the molecular formula C9H9N3. It is an indazole derivative that contains a methyl group and an amino group on the 2-position of the indazole ring. 6-AMINO-2-METHYL-2H-INDAZOLE has been studied for its potential pharmaceutical applications, particularly in the development of new drugs for various medical conditions. Its unique structure and properties make it a promising candidate for further research and potential application in the pharmaceutical industry.

InChI:InChI=1/C8H9N3/c1-11-5-6-2-3-7(9)4-8(6)10-11/h2-5H,9H2,1H3

Upstream product

• 6850-22-2 2-methyl-6-nitro-2H-indazole 
• 77-78-1 dimethyl sulfate 
• 7597-18-4 6-nitroindazole 
• 74-88-4 methyl iodide 
• 590417-95-1 6-bromo-2-methyl-2H-indazole 
• 99-55-8 2-methyl-5-nitroaniline 
• 95-53-4 o-toluidine 

Downstream Products

• 474799-57-0 2-[(2-bromo-pyridin-4-ylmethyl)-amino]-N-(2-methyl-2H-indazol-6-yl)-benzamide 
• 1620059-35-9 C₁₅H₁₄ClN₅ 
• 1620059-17-7 5-[[4-[N-(2-methyl-2H-indazol-6-yl)-N-methylamino]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide 
• 1311986-79-4 N²-(3,5-dimethylphenyl)-N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)pyrimidine-2,4-diamine 
• 1311986-81-8 N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)-N²-(4-(trifluoromethoxy)phenyl)pyrimidine-2,4-diamine 
• 1311986-75-0 N²-(3-methoxyphenyl)-N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)pyrimidine-2,4-diamine 
• 1311986-77-2 N²-(3-chlorophenyl)-N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)pyrimidine-2,4-diamine 
• 1311986-73-8 N²-(3-fluorophenyl)-N⁴-methyl-N⁴-(2-methyl-2H-indazol-6-yl)pyrimidine-2,4-diamine 
• 1064152-85-7 2-Amino-N-(2-methyl-2H-indazol-6-yl)-benzamide 
• 128056-51-9 2-(4-Chloro-phenyl)-9-methyl-5,9-dihydro-2H-1,2,5,9,10-pentaaza-dicyclopenta[a,h]naphthalen-3-one 
• 52470-67-4 2-methyl-6-hydroxyindazole 
• 132283-43-3 2-(2-Methyl-2H-indazol-6-ylamino)-benzoic acid 
• 112635-17-3 2-Methyl-7,8-diphenyl-2,6-dihydro-pyrrolo[2,3-g]indazole 

Relevant articles and documents

Design, synthesis and bioevaluation of novel 6-substituted aminoindazole derivatives as anticancer agents

In the present study, a series of 6-substituted aminoindazole derivatives were designed, synthesized, and evaluated for bio-activities. The compounds were initially designed as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors based on the structural feature of five IDO1 inhibitors, which are currently on clinical trials, and the important anticancer activity of the indazole scaffold. One of them, compound N-(4-fluorobenzyl)-1,3-dimethyl-1H-indazol-6-amine (36), exhibited a potent anti-proliferative activity with an IC50 value of 0.4 ± 0.3 μM in human colorectal cancer cells (HCT116). This compound also remarkably suppressed the IDO1 protein expression. In the cell-cycle studies, the suppressive activity of compound 36 in HCT116 cells was related to the G2/M cell cycle arrest. Altogether, the current findings demonstrate that compound 36 would be promising for further development as a potential anticancer agent.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharma

Discovery and synthesis of N2,N4-substitued- cycloalkyl[d]pyrimidine-2,4-diamine analogs: The first examples of small-molecular FGFR-1 activator

A series of novel, cycloalkyl-modified pazopanib analogs 2 and 3 were designed and synthesized. Their kinase modulatory effects on FGFR-1, VEGFR-2, PDGFR-β, and c-KIT were evaluated by the caliper mobility shift assay. Introduction of cycloalkyl into the pyrimidine linker of pazopanib almost abolished the four kinases inhibitory potency of compounds 2 and 3, but surprisingly, resulted in good activation effects on FGFR-1. Compounds 3d and 3g showed double-digit, nanomolar, selective activation effects on FGFR-1, and could be classified as first-generation small molecular activators of FGFR-1 kinase.